| scholarly article | Q13442814 |
| P356 | DOI | 10.1007/S10928-014-9354-4 |
| P698 | PubMed publication ID | 24651961 |
| P2093 | author name string | Kayode Ogungbenro | |
| Leon Aarons | |||
| CRESim & Epi-CRESim Project Groups | |||
| P2860 | cites work | Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis | Q28285444 |
| Membrane transporters in drug development | Q29616802 | ||
| Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. | Q33723702 | ||
| The fourth dimension of life: fractal geometry and allometric scaling of organisms. | Q33863970 | ||
| Prediction of the clearance of eleven drugs and associated variability in neonates, infants and children | Q33998916 | ||
| Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer | Q34055165 | ||
| The pharmacokinetics of methotrexate and its 7-hydroxy metabolite in patients with rheumatoid arthritis | Q34403636 | ||
| A formula to estimate the approximate surface area if height and weight be known. 1916. | Q34437560 | ||
| Geometric method for measuring body surface area: a height-weight formula validated in infants, children, and adults | Q34662040 | ||
| Pharmacogenetic and metabolite measurements are associated with clinical status in patients with rheumatoid arthritis treated with methotrexate: results of a multicentred cross sectional observational study | Q35555878 | ||
| Rare versus common variants in pharmacogenetics: SLCO1B1 variation and methotrexate disposition | Q35634476 | ||
| Dosing algorithm to target a predefined AUC in patients with primary central nervous system lymphoma receiving high dose methotrexate. | Q35718598 | ||
| The population pharmacokinetics of long-term methotrexate in rheumatoid arthritis | Q35803314 | ||
| Dose standardisation of anticancer drugs | Q83520098 | ||
| Comparison of pharmacokinetics and toxicity after high-dose methotrexate treatments in children with acute lymphoblastic leukemia | Q85553441 | ||
| Quantitative justification for target concentration intervention--parameter variability and predictive performance using population pharmacokinetic models for aminoglycosides. | Q35826231 | ||
| Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients. | Q35827596 | ||
| Absorption of methotrexate under standardized conditions in children with acute lymphoblastic leukaemia | Q36044389 | ||
| Genome-wide study of methotrexate clearance replicates SLCO1B1. | Q36595293 | ||
| Multiexponential, multicompartmental, and noncompartmental modeling. II. Data analysis and statistical considerations | Q36625384 | ||
| A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam | Q36910537 | ||
| Population-based mechanistic prediction of oral drug absorption | Q37214520 | ||
| Protein binding predictions in infants | Q37361786 | ||
| A population pharmacokinetic model for low-dose methotrexate and its polyglutamated metabolites in red blood cells | Q39453054 | ||
| Age-related pharmacokinetics of high-dose methotrexate in patients with osteosarcoma | Q40585977 | ||
| Clinical pharmacokinetics of low-dose pulse methotrexate in rheumatoid arthritis | Q41177632 | ||
| Population pharmacokinetics of high-dose methotrexate after intravenous administration in pediatric patients with osteosarcoma | Q42605998 | ||
| Aspirin alters methotrexate disposition in rheumatoid arthritis patients | Q44790474 | ||
| Preliminary Model for Methotrexate Pharmacokinetics | Q44809790 | ||
| Pharmacokinetics of oral methotrexate in patients with rheumatoid arthritis | Q45081072 | ||
| Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis | Q45134701 | ||
| A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma | Q45378666 | ||
| Coadministration of naproxen and low-dose methotrexate in patients with rheumatoid arthritis | Q45895196 | ||
| A pilot study of pharmacokinetically guided dosing of oral methotrexate in the initial phase of psoriasis treatment | Q46887359 | ||
| Pharmacokinetics of oral methotrexate in children. | Q51647048 | ||
| Age-related changes in laboratory values used in the diagnosis of anemia and iron deficiency. | Q51659287 | ||
| Development and evaluation of a generic physiologically based pharmacokinetic model for children. | Q51933198 | ||
| Low-dose methotrexate kinetics in arthritis. | Q52695476 | ||
| The kinetics of methotrexate distribution in spontaneous canine lymphosarcoma | Q52879627 | ||
| Physiologically based pharmacokinetic modeling of intestinal first-pass metabolism of CYP3A substrates with high intestinal extraction. | Q53084883 | ||
| CLINICAL CALORIMETRY | Q56391094 | ||
| Methotrexate polyglutamate levels in circulating erythrocytes and polymorphs correlate with clinical efficacy in rheumatoid arthritis. | Q64897563 | ||
| The effect of food on the absorption of methotrexate sodium tablets in healthy volunteers | Q68191438 | ||
| Methotrexate bioavailability after oral and intramuscular administration in children | Q68758237 | ||
| Biliary elimination of low-dose methotrexate in humans | Q68839171 | ||
| Transport and Binding of Methotrexate In Vivo | Q69539183 | ||
| Pharmacokinetics of low-dose methotrexate in rheumatoid arthritis patients | Q69601502 | ||
| The pharmacokinetics of 7-hydroxymethotrexate following medium-dose methotrexate therapy | Q70058397 | ||
| Bioavailability of methotrexate tablets | Q70436219 | ||
| Methotrexate Pharmacokinetics | Q70620597 | ||
| Pharmacokinetics of Sustained Serum Methotrexate Concentrations Secondary to Gastrointestinal Obstruction | Q70978443 | ||
| Pharmacokinetics and Organ Distribution of Methotrexate in the Rat | Q71015277 | ||
| Pharmacokinetics of methotrexate and 7-hydroxymethotrexate following infusions of high-dose methotrexate | Q72049096 | ||
| Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia | Q72063971 | ||
| Lack of pharmacokinetic interaction of meloxicam with methotrexate in patients with rheumatoid arthritis | Q73337081 | ||
| Pharmacokinetics and pharmacodynamics of oral methotrexate and mercaptopurine in children with lower risk acute lymphoblastic leukemia: a joint children's cancer group and pediatric oncology branch study | Q77531744 | ||
| The effect of malignant effusions on methotrexate disposition | Q78536679 | ||
| Basic anatomical and physiological data for use in radiological protection: reference values. A report of age- and gender-related differences in the anatomical and physiological characteristics of reference individuals. ICRP Publication 89 | Q79079499 | ||
| Impact of Abcc2 (Mrp2) and Abcc3 (Mrp3) on the in vivo elimination of methotrexate and its main toxic metabolite 7-hydroxymethotrexate | Q82994724 | ||
| P433 | issue | 2 | |
| P921 | main subject | methotrexate | Q422232 |
| pharmacokinetics | Q323936 | ||
| mercaptopurine | Q418529 | ||
| P304 | page(s) | 159-171 | |
| P577 | publication date | 2014-03-21 | |
| P1433 | published in | Journal of Pharmacokinetics and Pharmacodynamics | Q15766045 |
| P1476 | title | Physiologically based pharmacokinetic modelling of methotrexate and 6-mercaptopurine in adults and children. Part 1: methotrexate | |
| P478 | volume | 41 |
| Q35924108 | Effect of methotrexate on cerebellar development in infant rats |
| Q64042976 | Innovative Study Designs Optimizing Clinical Pharmacology Research in Infants and Children |
| Q48232372 | Is it really safe to withhold folinic acid when less than 1000 mg/m2 methotrexate is ingested? |
| Q38923085 | Key to Opening Kidney for In Vitro-In Vivo Extrapolation Entrance in Health and Disease: Part II: Mechanistic Models and In Vitro-In Vivo Extrapolation |
| Q46244052 | Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics. |
| Q38527434 | Modeling and simulation in pediatric drug therapy: Application of pharmacometrics to define the right dose for children |
| Q36072504 | Optimizing pharmacokinetic bridging studies in paediatric oncology using physiologically-based pharmacokinetic modelling: application to docetaxel |
| Q38758820 | Physiologically Based Pharmacokinetic Modeling in Pediatric Oncology Drug Development |
| Q41368460 | Physiologically based pharmacokinetic model for 6-mercpatopurine: exploring the role of genetic polymorphism in TPMT enzyme activity |
| Q64072336 | Strategies for the Induction of Immune Tolerance to Enzyme Replacement Therapy in Mucopolysaccharidosis Type I |
| Q38812692 | Usefulness of PBPK Modeling in Incorporation of Clinical Conditions in Personalized Medicine |
Search more.